to test the efficacy of inhaled pulmonary surfactant replacement therapy in adults with COVID-19 disease | Pandemic PACT Tracker

Key facts

Disease
COVID-19
start year
2020
Known Financial Commitments (USD)
$1,648,270
Funder
Gates Foundation
Principal Investigator
N/A
Research Location
United Kingdom
Lead Research Institution
The University of Southampton
Research Priority Alignment
N/A

Research Category
Clinical characterisation and management
Research Subcategory
Supportive care, processes of care and management
Special Interest Tags
N/A
Study Type
Clinical
Clinical Trial Details
Not applicable
Broad Policy Alignment
Pending
Age Group
Adults (18 and older)
Vulnerable Population
Unspecified
Occupations of Interest
Unspecified

Abstract

N/A

Publicationslinked via Europe PMC

Last Updated:42 minutes ago

View all publications at Europe PMC

A randomized controlled trial of nebulized surfactant for the treatment of severe COVID-19 in adults (COVSurf trial).

Surfactant Proteins SP-B and SP-C in Pulmonary Surfactant Monolayers: Physical Properties Controlled by Specific Protein-Lipid Interactions.

Identification of a New Cholesterol-Binding Site within the IFN-γ Receptor that is Required for Signal Transduction.

Nebulised surfactant for the treatment of severe COVID-19 in adults (COV-Surf): A structured summary of a study protocol for a randomized controlled trial.